Updated Story DaVita officials provided investors with more insight into the company's decision to immediately stop helping Medicaid-eligible patients get additional exchange coverage with the help of the American Kidney Fund, while also arguing the assistance efforts have only slightly increased end-stage renal disease-related plan spending despite insurers' assertions to the contrary. In a Wednesday call, DaVita officials said their move was only temporary and would be reevaluated once CMS releases additional guidance. DaVita made the decision...